GILEAD SCIENCES, INC.

SUNLENCA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

GILEAD SCIENCES, INC.

Sunlenca HCPCS:

J1961

HCPCS Code Descriptor:

Injection, lenacapavir, 1 mg

Category:

J Code

Sunlenca NDCs:

61958-3002-01

Primary Type:

Anti-HIV

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Sunlenca CPT Codes:

Potential CPT administration codes for Sunlenca can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

61958-3002-01

About Sunlenca:

SUNLENCA is a Anti-HIV drug manufactured by GILEAD SCIENCES, INC. and administered via the Subcutaneous route of administration. The J Code: J1961 is aligned to the drug SUNLENCA.

SUNLENCA belongs to the class of drugs known as capsid inhibitors and affects the capsid of certain viruses hindering their replication process. This medication is often used to treat patients with a virus that causes an autoimmune deficiency. Sunleca is a branded drug manufactured by Gilead Sciences and is currently aligned with the HCPCS code J1961. Patient assistance programs for this medication can be found through Gilead’s Advancing Access program.

ACCESS PRICING AND MORE BY REGISTERING

J1961 Added Date:

July 1, 2023

J1961 Effective Date:

July 1, 2023

J1961 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Sunlenca billing and coding information.
Sunlenca patient assistance information can be found through Gilead Advancing Access at the URL: https://www.gileadadvancingaccess.com/
SUNLENCA prescribing information can be found at the link below:
Information regarding SUNLENCA’s side effects can be found at MedlinePlus